Pular para o conteúdo
Merck
Todas as fotos(2)

Documentos

L8793

Sigma-Aldrich

Anti-LC3A antibody produced in rabbit

~1 mg/mL, affinity isolated antibody, buffered aqueous solution

Sinônimo(s):

Anti-MAP1 light chain 3-like protein 1, Anti-MAP1A/1B light chain 3 A, Anti-MAP1A/MAP1B LC3 A, Anti-MAP1ALC3, Anti-MAP1BLC3, Anti-MAP1LC3A, Anti-Microtubule-associated protein 1 light chain 3 alpha

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Código UNSPSC:
12352203
NACRES:
NA.41

fonte biológica

rabbit

conjugado

unconjugated

forma do anticorpo

affinity isolated antibody

tipo de produto de anticorpo

primary antibodies

clone

polyclonal

forma

buffered aqueous solution

peso molecular

antigen 16-18 kDa

reatividade de espécies

mouse, human, rat

concentração

~1 mg/mL

técnica(s)

immunoprecipitation (IP): 5-10 μg using extracts of human U87 cells
western blot: 0.5-1 μg/mL using whole extracts of rat and mouse brain

nº de adesão UniProt

Condições de expedição

dry ice

temperatura de armazenamento

−20°C

modificação pós-traducional do alvo

unmodified

Informações sobre genes

Descrição geral

Microtubule-associated proteins 1A/1B light chain 3 or MAP1LC3 is a cellular protein that is involved in the formation of autophagosomes . MAP1LC3 genes have three known human isoforms, namely, MAP1LC3A, MAP1LC3B and MAP1LC3C. These isoforms have different responses to amino acid starvation and varied sub-cellular localization patterns . Anti-LC3A antibody reacts with human and rat LC3A-I (approx. 18 kDa) and LC3A-II (approx. 16 kDa) by immunoblotting and immunoprecipitation. The antibody is also specific for mouse LC3A-I (approx. 18 kDa). Specific cell treatment and/or long exposure may be required for the detection of mouse LC3A-II. The immunizing peptide specifically inhibits the detection of the LC3A bands by immunoblotting.

Especificidade

Anti-LC3A antibody recognizes human and rat microtubule-associated protein light chain 3-A (LC3A-I) and LC3A-II by immunoblotting and immunoprecipitation (~18 kDa and ~16 kDa, respectively) and mouse LC3A-I (~18 kDa).

Imunogênio

Synthetic peptide corresponding to amino acids of human LC3A isoform α, conjugated to KLH via C-terminal cysteine residue. The corresponding sequence is identical in rat and mouse.

Aplicação

Anti-LC3A antibody produced in rabbit has been used in
  • immunohistochemistry
  • immunostaining
  • western blotting

Ações bioquímicas/fisiológicas

Microtubule-associated protein light chain 3-I (LC3-I) is modified to a membrane-bound form, LC3-II (a LC3-phospholipid conjugate), by mammalian autophagy related 7 (Atg7) and Atg3, which are E1- and E2-like enzymes, respectively. The amount of LC3 II correlates with the extent of autophagosome formation. LC3A can also be as an autophagosomal marker.

forma física

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.

Armazenamento e estabilidade

For continuous use, store at 2-8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in “frost-free” freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.

Exoneração de responsabilidade

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Ferramenta de seleção de produtos.

Código de classe de armazenamento

10 - Combustible liquids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)


Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Xuekai Zhang et al.
Alzheimer's research & therapy, 6(9), 78-78 (2015-01-27)
Many neurodegenerative diseases are characterised by accumulations of misfolded proteins that can colocalise with chaperone proteins (for example, heat shock protein 27 (HSP27)), which might act as modulators of protein aggregation. The role of HSP27 in the pathogenesis of neurodegenerative
Fangqin Yu et al.
Frontiers in oncology, 11, 638701-638701 (2021-05-04)
Thyroid cancer is one of the most common endocrine malignancies worldwide, and papillary thyroid cancer (PTC) is the most common pathologic type of thyroid cancer. SQSTM1/p62 activity mediates different biological functions. This study aimed to investigate the effect of SQSTM1/p62
Rowan Gurney et al.
Neuropathology : official journal of the Japanese Society of Neuropathology (2018-05-12)
A failure of protein degradation may underpin Lewy body disease (LBD) where α-synuclein is assimilated into the pathognomic Lewy bodies and Lewy neurites. We investigated histological alterations in lysosomes and autophagosomes in the substantia nigra (SN) and cingulate gyrus (CG)
João Cláudio Damasceno-Sá et al.
Memorias do Instituto Oswaldo Cruz, 116, e200417-e200417 (2021-03-18)
Toxoplasma gondii causes toxoplasmosis and is controlled by activated macrophages. However, infection of macrophages by tachyzoites induces TGF-β signaling (TGF-s) inhibiting nitric oxide (NO) production. NO inhibition may be a general escape mechanism of distinct T. gondii strains. To evaluate
Kaito Nihira et al.
The Journal of pathology, 234(2), 277-288 (2014-04-02)
The development of therapeutic resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs, ie erlotinib or gefitinib) has been the major clinical problem when treating lung adenocarcinoma patients with these agents. However, its mechanisms have not necessarily been well studied to this

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica